196500-31-9

Upstream product

• 13139-14-5 Boc-Trp-OH 
• 1053644-74-8 (4aS,5R)-5-Amino-2-benzyl-hexahydro-pyrido[1,2-c]pyrimidine-1,3-dione 
• 1219132-56-5 ((2S,3R)-3-tert-Butoxycarbonylamino-piperidin-2-yl)-acetic acid ethyl ester 
• 150618-13-6 ((2R,3S)-3-tert-Butoxycarbonylamino-piperidin-2-yl)-acetic acid ethyl ester 
• 3173-56-6 benzyl isothiocyanate 

Relevant academic research and scientific papers

Synthesis and stereochemical structure activity relationships of 1,3- dioxoperhydropyrido[1,2-c]pyrimidine derivatives: Potent and selective cholecystokinin-a receptor antagonists

The synthesis and stereochemical structure-activity relationships of a new class of potent and selective non-peptide cholecystokinin-A (CCK-A) receptor antagonists based on the 1,3-dioxoperhydropyrido[1,2-c]pyrimidine skeleton are described. The most potent member of this series of eight diastereoisomers, (4aS,5R)-2-benzyl-5-[N-[(tert-butoxycarbonyl)-L- tryptophyl]-amino]-1,3-dioxoperhydropyrido[1,2-c]pyrimidine, displays nanomolar CCK-A receptor affinity and higher than 8000-fold potency at the CCK-A than at the CCK-B receptor. As CCK-A antagonist, this compound inhibits the CCK-8-evoked amylase release from pancreatic acinar cells at a low concentration, similar to that of the typical antagonist Devazepide. Highly strict stereochemical requirements for CCK-A receptor binding and selectivity have been found. The L-Trp and the 4a,5-trans disposition of the bicyclic perhydropyrido[1,2-c]pyrimidine are essential for binding potency and selectivity.